Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

pediatrics

- PMLiVE

Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy

The company said it is planning to file regulatory applications for OAV101 IT this year

- PMLiVE

Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study

It is estimated that nearly 320,000 people will be diagnosed with the disease in the US this year

- PMLiVE

Roche to launch new innovation centre at Harvard’s Enterprise Research Campus

The first phase of construction on the ERC is expected to be complete in 2026

Biogen Idec building

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

The trial will evaluate the candidate in patients with antibody-mediated rejection

- PMLiVE

Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

The companies will develop petrelintide as both a standalone therapy and in combination with Roche’s CT-388

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

Biogen Idec building

Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m

The rare genetic epilepsy affects up to 38,000 people in the US, UK, EU and Japan

- PMLiVE

Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

- PMLiVE

Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma

Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease

- PMLiVE

Roche announces positive late-stage results for Gazyva/Gazyvaro in lupus nephritis

The disease affects approximately 1.7 million people worldwide and primarily impacts women

- PMLiVE

Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer

An estimated 154,270 people will be diagnosed with cancer of the colon or rectum in the US this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links